---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-069605"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2024-06-07T23:59:59+00:00"
generated_at: "2026-06-01T05:40:28.615823+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# TransCode Therapeutics regains Nasdaq minimum bid price compliance; hearing cancelled

## Summary
- Received Nasdaq letter on June 3, 2024 confirming compliance with Listing Rule 5550(a)(2).
- Hearing scheduled for June 25, 2024 has been cancelled.
- Remains under mandatory panel monitor through January 27, 2025.
- Ticker RNAZ; stock continues on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001104659-24-069605
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2024-06-07T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465924069605/0001104659-24-069605-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465924069605/tm2416749d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-069605
- JSON: https://secwatch.observer/filing/0001104659-24-069605.json
- Plain text: https://secwatch.observer/filing/0001104659-24-069605.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.